ライフサイエンスコーパス: etoposide

1 the treatment of two drugs (doxorubicin and etoposide).

2 by 3 cycles of ICE (ifosfamide, carboplatin, etoposide).

3 e to the anti-cancer drug and TOP2 inhibitor etoposide.

4 osine arabinoside (ara-C), daunorubicin, and etoposide.

5 nsist of four cycles of a platinum agent and etoposide.

6 se (5 muM) of the topoisomerase II inhibitor etoposide.

7 ier function following exposure to high-dose etoposide.

8 ange enhanced the effects of camptothecin or etoposide.

9 ction of apoptosis by the DNA-damaging agent etoposide.

10 e highly resistant to ATRA, doxorubicin, and etoposide.

11 inst cell death induced by dexamethasone and etoposide.

12 d with the DNA-damaging agents cisplatin and etoposide.

13 to topoisomerase II (topo II) inhibition by etoposide.

14 -strand breaks in response to doxorubicin or etoposide.

15 n, paclitaxel, vinblastine, vincristine, and etoposide.

16 n response to tumor necrosis factor (TNF) or etoposide.

17 following exposure to the DNA-damaging agent etoposide.

18 n Top2beta-DNA covalent complexes induced by etoposide.

19 nced response to the topoisomerase-II poison etoposide.

20 ll sensitivity to the Topo II-targeting drug etoposide.

21 LC) are carboplatin-paclitaxel and cisplatin-etoposide.

22 or the expression of ZNF281 and treated with etoposide.

23 ders cells sensitive to the anticancer agent etoposide.

24 by treatment with the chemotherapeutic agent etoposide.

25 hemotherapeutic drugs, that is, cisplatin or etoposide.

26 PEI) at total doses of platinum 420 mg/m(2), etoposide 1,200 mg/m(2), and ifosfamide 30 g/m(2).

27 g/m(2) (both arms), epirubicin 450 mg/m(2), etoposide 1,350 mg/m(2) (six-drug regimen).

28 s of high-dose carboplatin 1,500 mg/m(2) and etoposide 1,500 mg/m(2) (CE, arm A) or three cycles of V

29 ycle of high-dose carboplatin 2,200 mg/m(2), etoposide 1,800 mg/m(2), and cyclophosphamide 6,400 mg/m

30 The use of induction low-dose etoposide 100 mg/m(2) and cisplatin 20 mg/m(2) (EP; days

31 atin area under the curve of 5 on day 1 plus etoposide 100 mg/m(2) per day on days 1 to 3 every 21 da

32 rum concentration-time curve 5 on day 1 plus etoposide 100 mg/m(2) per day on days 1 to 3 every 21 da

33 th equidose mesna uroprotection, followed by etoposide 100 mg/m(2) per day over 1 h on days 1-5.

34 rum concentration-time curve 4 on day 1 plus etoposide 100 mg/m(2) per day plus palifosfamide 130 mg/

35 n day -12), carmustine 300 mg/m(2) (day -6), etoposide 100 mg/m(2) twice daily (days -5 to -2), cytar

36 eceive mitotane plus either a combination of etoposide (100 mg per square meter of body-surface area

37 s cisplatin [20 mg/m(2) per day for 5 days], etoposide [100 mg/m(2) per day for 5 days], and intramus

38 cycles (cisplatin 33 mg/m(2) on days 1 to 3, etoposide 167 mg/m(2) on days 1 to 3, bleomycin 15 U/m(2

39 for total doses of platinum 420 mg/m(2) and etoposide 2,040 mg/m(2).

40 of carboplatin AUC 5, day 3; three doses of etoposide 200 mg/m(2) every 12 h, day 1) before consider

41 Topo I (camptothecin, 34%) and 20% Topo II (etoposide 24%) at 20 muM.

42 3l inhibited 61% Topo II (etoposide 24%) at 20 muM.

43 h either one cycle of cisplatin 100 mg/m(2), etoposide 375 mg/m(2), and ifosfamide 6 g/m(2) (VIP) plu

44 m2) alternating with ifosfamide (9 g/m2) and etoposide (500 mg/m2) for 14 cycles, with filgrastim (5

45 2) on days 2 through 5 (total 6 g/m(2)), and etoposide 700 mg/m(2) per day on days 2 through 4 (total

46 ith cytarabine 100 mg/m(2) daily for 5 days, etoposide 75 mg/m(2) daily for 5 days, and idarubicin 9

47 latin 700 mg/m(2) on days -5, -4, and -3 and etoposide 750 mg/m(2) on days -5, -4, and -3.

48 s reduced by lowering the cumulative dose of etoposide (950 to 450 mg/m(2)) and intrathecal central n

49 did not occur when ABT-737 was combined with etoposide, a gold-standard cytotoxic for SCLC therapy.

50 The moderate and temporally limited use of etoposide, a topoisomerase inhibitor, to eliminate encep

51 Etoposide, a widely used chemotherapeutic drug that inhi

52 orubicin and cytarabine (DA) with or without etoposide (ADE; n = 1983) or ADE versus fludarabine, cyt

53 nts with HL treated with BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, pr

54 two cycles of escalated BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, pr

55 Our results enable production of the etoposide aglycone in tobacco and circumvent the need fo

56 y to (-)-4'-desmethylepipodophyllotoxin (the etoposide aglycone), a naturally occurring lignan that i

57 Etoposide also increased PID1 promoter reporter activity

58 B patients were treated with carboplatin and etoposide, alternating with cyclophosphamide, idarubicin

59 iological evaluation of a focused library of etoposide analogues, with the identification of two nove

60 totic agents tumor necrosis factor alpha and etoposide and are the first to confirm ks-vFLIP as a tra

61 with cisplatin, melphalan, camptothecin, or etoposide and assayed for colony formation.

62 to high-dose chemotherapy with thiotepa and etoposide and autologous peripheral blood stem-cell resc

63 NF-kappaB activation by BRCA1 in response to etoposide and camptothecin is demonstrated by the signif

64 ng agents mitomycin C and Irofulven, but not etoposide and camptothecin, suggesting a role in nucleot

65 fference in response rates between cisplatin-etoposide and carboplatin-paclitaxel (58% vs 56%; P = .2

66 outcomes and toxic effects between cisplatin-etoposide and carboplatin-paclitaxel in patients with no

67 Cisplatin-etoposide and carboplatin-paclitaxel regimens were assoc

68 current chemotherapy consisting of cisplatin/etoposide and chest radiotherapy, resulting in a marked

69 cancer survivors (TCSs) after four cycles of etoposide and cisplatin (EPX4) or three or four cycles o

70 une 2010, he was treated with four cycles of etoposide and cisplatin for pulmonary and thoracic lymph

71 Etoposide and cisplatin increased NFkappaB promoter repo

72 The median cumulative doses of doxorubicin-etoposide and cyclophosphamide administered in the SC-EP

73 and thalidomide with alternating periods of etoposide and cyclophosphamide, whereas the other arm re

74 nd causes sensitization to DNA-damaging drug etoposide and DNA repair inhibitor olaparib.

75 ss the treatment response to the neoadjuvant etoposide and found a consistent and reliable improvemen

76 ine key structural elements of merbarone and etoposide and generated new type II topoisomerase (topoI

77 nterfering RNA promoted apoptosis induced by etoposide and increased EV71 release.

78 and trametinib potentiated tumor response to etoposide and increased overall survival.

79 Our results revealed the cytotoxins etoposide and ivermectin as potent inducers, allowing us

80 n-ATP-competitive inhibitors of TopoIIalpha, etoposide and merbarone, were ineffective at preventing

81 ansforms the topoisomerase II (TOP2) poisons etoposide and mitoxantrone to chemical forms that have a

82 and cisplatin (VIPx4) instead of bleomycin, etoposide and platinum (BEPx4) to prevent pulmonary comp

83 pretreatment with dasatinib also suppressed etoposide and radiation induced apoptosis in vitro.

84 enes was downregulated in cells treated with etoposide and silenced for ZNF281.

85 of TDP2 sensitizes mtp53-expressing cells to etoposide and that mtp53 and TDP2 are frequently overexp

86 P2ccs can be trapped by cancer drugs such as etoposide and then converted into DNA double-strand brea

87 truct were sensitive to apoptosis induced by etoposide and TNF-alpha.

88 onses concerning treatment with doxorubicin, etoposide and vincristine.

89 ng lignan that is the immediate precursor of etoposide and, unlike podophyllotoxin, a potent topoisom

90 It is treated with immune suppressants, etoposide, and allogeneic hematopoietic stem cell transp

91 s (MGCT) if the administration of cisplatin, etoposide, and bleomycin (PEb) is reduced from four to t

92 chemotherapy with compressed PEB (cisplatin, etoposide, and bleomycin) was initiated every 3 weeks fo

93 up A patients were treated with vincristine, etoposide, and carboplatin (VEC) and group B patients we

94 temic chemotherapy with vincristine sulfate, etoposide, and carboplatin had failed in 10 patients (91

95 motherapy with a combination of vincristine, etoposide, and carboplatin in patients with focal vitreo

96 Following IVC (vincristine, etoposide, and carboplatin), adjuvant treatments include

97 n hypothesized for treatment with bleomycin, etoposide, and cisplatin (BEP).

98 etroperitoneal radiotherapy (RT); bleomycin, etoposide, and cisplatin (BEP); or more than 1 line of t

99 nse to other cytotoxic agents such as TRAIL, etoposide, and cycloheximide.

100 plerixafor in combination with mitoxantrone, etoposide, and cytarabine.

101 , vincristine, cyclophosphamide, ifosfamide, etoposide, and dactinomycin and identified prognostic fa

102 and doxorubicin or vincristine, prednisone, etoposide, and doxorubicin chemotherapy; additional two

103 including neocarzinostatin, gamma rays, and etoposide, and found that H3K36me3 and H4K16ac were both

104 orubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for H

105 r agents, including ionizing radiation (IR), etoposide, and hydrogen peroxide.

106 to busulfan and melphalan or to carboplatin, etoposide, and melphalan by minimisation, balancing age

107 lan group and 188 of 302 in the carboplatin, etoposide, and melphalan group had an event; 3-year even

108 d melphalan group and 11 in the carboplatin, etoposide, and melphalan group had died without relapse

109 roup vs 103 [38%] of 270 in the carboplatin, etoposide, and melphalan group), infection (55 [19%] of

110 se versus 21 (9%) of 239 in the carboplatin, etoposide, and melphalan group.

111 The carboplatin, etoposide, and melphalan regimen consisted of carboplati

112 severe adverse events than did carboplatin, etoposide, and melphalan.

113 fan and melphalan compared with carboplatin, etoposide, and melphalan.

114 sulfan and melphalan and 302 to carboplatin, etoposide, and melphalan.

115 elphalan and at least 72 h after carboplatin etoposide, and melphalan.

116 halan and 29 (10%) who received carboplatin, etoposide, and melphalan.

117 ubicin, vinblastine, vincristine, bleomycin, etoposide, and prednisone (Stanford V) in G studies.

118 ubicin, vincristine, bleomycin, vinblastine, etoposide, and prednisone (Stanford V).

119 (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone) was administered (in patients

120 da; n = 1268), and to amsacrine, cytarabine, etoposide, and then mitoxantrone/cytarabine (MACE-MidAC)

121 entiating the biologic effects of celecoxib, etoposide, and TRAIL.

122 ese data demonstrate for the first time that etoposide- and cisplatin-induced apoptosis in medullobla

123 e activity leads to elevated accumulation of etoposide- and mitoxantrone-induced TOP2A and TOP2B-DNA

124 ng in an increased Bcl-2 level and decreased etoposide- and UV/gamma radiation-mediated DNA fragmenta

125 targeting poisons such as anthracyclines and etoposide are commonly used for cancer chemotherapy and

126 erase poisons such as the epipodophyllotoxin etoposide are widely used effective cytotoxic anticancer

127 ly assigned to receive either cisplatin plus etoposide (arm A) or the same regimen with bevacizumab (

128 volved in the repair of DNA damage caused by etoposide, as a transcriptional target of mtp53.

129 ) and augmented ifosfamide, carboplatin, and etoposide (augICE), we assessed clinical factors, quanti

130 nced ABCB5 positivity after carboplatin- and etoposide-based chemotherapy, pointing to clinical signi

131 rapy entailing three cycles of cisplatin and etoposide before radiation (chemotherapy first [CT1]) or

132 ation (IVA plus carboplatin, epirubicin, and etoposide) both delivered over 27 weeks.

133 initially highly responsive to cisplatin and etoposide but in almost every case becomes rapidly chemo

134 kt signaling synergized with camptothecin or etoposide, but higher A-443654 or MK-2206 concentrations

135 cytarabine, 6-thioguanine, doxorubicin, and etoposide, but not to a non-DNA damaging agent, l-aspara

136 erapy to 60 Gy in 6 wk with either cisplatin/etoposide (C/E, n = 28) weeks 1 and 5 or weekly carbopla

137 Topoisomerase II (Topo II) poisons such as etoposide can induce abortive DNA strand breaks in which

138 Etoposide caused a dose-dependent increase in the gammaH

139 tarting on day 22 after commencing cisplatin-etoposide chemotherapy (given as four to six cycles ever

140 the donor patient's response to platinum and etoposide chemotherapy.

141 (EPX4) or three or four cycles of bleomycin, etoposide, cisplatin (BEPX3/BEPX4).

142 with or without two cycles of dexamethasone, etoposide, cisplatin, and cytarabine (DECA).

143 reatment with chemotherapeutic drugs such as etoposide, cisplatin, and imatinib.

144 e Veterans Health Administration with either etoposide-cisplatin (EP) or carboplatin-paclitaxel (CP).

145 group 1 epipodophyllotoxins (teniposide and etoposide) consistently produced the greatest transducti

146 The topoisomerase II poisons doxorubicin and etoposide constitute longstanding cornerstones of chemot

147 curve 4.1 mg/mL per min per day for 4 days, etoposide continuous infusion of 338 mg/m(2) per day for

148 Patients were prepared using carmustine, etoposide, cytarabine, and melphalan and received consis

149 eceived high-dose treatment with carmustine, etoposide, cytarabine, and melphalan as well as rabbit a

150 igh-dose BEAM/C (bis-chloroethylnitrosourea, etoposide, cytarabine, and melphalan or cyclophosphamide

151 This effect was remarkably selective; etoposide did not exert a direct anti-inflammatory effec

152 n by macrophages, whereas cells treated with etoposide did not.

153 he chemotherapeutical agents gemcitabine and etoposide distinctively.

154 rospective study of infusional dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincri

155 rospective study of infusional dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincri

156 ow-intensity treatment consisting of infused etoposide, doxorubicin, and cyclophosphamide with vincri

157 Anticancer drugs (etoposide, doxorubicin, and mitoxantrone) and also Top2

158 s two standard cycles of BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, p

159 w-up, 106 months), superiority of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, p

160 EACOPP(escalated) (escalated-dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, p

161 After six to eight cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, p

162 atients switched to two cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, p

163 nfavorable HIV-HL, four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, p

164 to 5) were switched to escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, p

165 fter two cycles received BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, p

166 strate that the combination of temozolomide, etoposide, doxorubicin, dexamethasone, rituximab, and th

167 DSBs, as well as for cellular resistance to etoposide during genomic DNA replication.

168 eclinical synergy, a phase 1 trial of T plus etoposide (E) yielded 25% complete remission (CR).

169 g of 700 mg/m(2) carboplatin and 750 mg/m(2) etoposide, each for 3 consecutive days, and each followe

170 h as the topoisomerase II (TopoII) inhibitor etoposide effectively reduce disease in a minority of pa

171 tment with the conventional chemotherapeutic etoposide equivalently enhanced the survival of both str

172 Genetic deletion of PDCD5 abrogates etoposide (ET)-induced p53 stabilization and HDAC3 cleav

173 Etoposide (ETO) is a commonly used chemotherapeutic drug

174 duced by topoisomerase inhibitors, including etoposide (ETO), results in a potent block to HIV-1 infe

175 in G2/M checkpoint activation in response to etoposide (ETOP) treatment.

176 terial gyrase, GSK299423, ciprofloxacin, and etoposide exhibited 15-, 57-, and 3-fold selectivity for

177 icacy of HDCT, consisting of carboplatin and etoposide followed by stem cell reinfusion, for the salv

178 -line recommendations or using platinum plus etoposide for those with large-cell neuroendocrine carci

179 s and doxorubicin had a higher efficacy than etoposide for treating hepatocellular carcinoma.

180 mice, to study the activity and mechanism of etoposide for treating HLH and found that it substantial

181 ing bevacizumab to first-line cisplatin plus etoposide for treatment of extensive-disease (ED) small-

182 re included from 31 studies in the cisplatin-etoposide groups (median age, 61 years; 65% male; 40% sq

183 y metastases, age, or doses of cisplatin and etoposide had no influence on follow-up PFT, and renal f

184 The TOP2 poison etoposide has been implicated in the generation of secon

185 sing cells recovered from cytotoxic doses of etoposide; however, LMP1 expression was sufficient for t

186 therapy, either ifosfamide, carboplatin, and etoposide (ICE) or dexamethasone, cytarabine, and cispla

187 ed by augmented ifosfamide, carboplatin, and etoposide (ICE).

188 for the DNA topoisomerase II (TOP2A) poison etoposide identified TOP2A, as expected, and also cyclin

189 He received four courses of etoposide, ifosfamide, and cisplatin chemotherapy, given

190 Seventy-six patients were treated with EIA (etoposide, ifosfamide, doxorubicin)+RHT (>/=5 cycles: 69

191 dose cytosine arabinoside, cyclophosphamide, etoposide, ifosphamide, corticosteroids, and triple intr

192 Remission was obtained with etoposide in 13 of 15 cases.

193 at inhibition of TOP2 religation activity by etoposide in AIRE-expressing cells had a synergistic eff

194 inding compound led to chemosensitization to etoposide in both in vitro and in vivo models.

195 addition of palifosfamide to carboplatin and etoposide in extensive stage (ES) small-cell lung cancer

196 eased the apoptosis induced by cisplatin and etoposide in medulloblastoma and glioblastoma cell lines

197 The addition of bevacizumab to cisplatin and etoposide in the first-line treatment of ED-SCLC had an

198 We found that the therapeutic mechanism of etoposide in this model system involved potent deletion

199 ally survived treatment with carboplatin and etoposide in vitro and in human MCC xenograft-bearing mi

200 nd find that cisplatin, cyclophosphamide and etoposide induce extra base substitutions with distinct

201 ethylbenz(a)anthracene (DMBA), cisplatin and etoposide induce nuclear DNA leakage into the cytosol th

202 ased NFkappaB promoter reporter activity and etoposide induced nuclear translocation of NFkappaB.

203 sion in SS was associated with resistance to etoposide-induced apoptosis and cell migration toward ch

204 Nrf2-activated tumor cells led to increased etoposide-induced apoptosis and decreased cell survival

205 ons, protecting up to 80% of neurons against etoposide-induced apoptosis at concentrations as low as

206 Moreover, although Trim39 loss inhibited etoposide-induced apoptosis in p53-negative cells, apopt

207 c-Src with shRNA decreased irradiation- and etoposide-induced apoptosis, suggesting that inhibitors

208 bile salt-induced apoptosis (BSIA) but also etoposide-induced apoptosis.

209 of Cdh1 stabilized MOAP-1, thereby enhancing etoposide-induced Bax activation and apoptosis.

210 aC were less sensitive to staurosporine- and etoposide-induced cell death, and silencing of VDAC1-Del

211 ion of miR-23a and miR-27a mimics attenuated etoposide-induced changes in Noxa, Puma, and Bax, reduce

212 ated with leukemic transformation, including etoposide-induced chromosomal breaks at the MLL and RUNX

213 We demonstrated that 2DG synergized with etoposide-induced cytotoxicity and significantly increas

214 Consistent with this, isoeugenol exacerbated etoposide-induced cytotoxicity, which generates TOP2-med

215 Etoposide-induced death of MLO-Y4 osteocyte-like cells,

216 hairpin RNA (shRNA) increases sensitivity to etoposide-induced DNA damage and neuronal cell death.

217 ability by RNF2 was also observed during the etoposide-induced DNA damage response.

218 We found that etoposide-induced DSBs are efficiently resected into 3'

219 In an etoposide-induced in vitro model of apoptosis in primary

220 n contrast, miRs hairpin inhibitors enhanced etoposide-induced neuronal apoptosis and caspase activat

221 The etoposide-induced protein Ei24 was initially identified

222 he defects in Mre11 compromise the repair of etoposide-induced Top2-DNA covalent complexes, and MRE11

223 Unlike moxifloxacin, QPT-1 and etoposide interact with conserved GyrB TOPRIM residues r

224 Because the toxicity of etoposide is pH-independent, there could be a more gener

225 y used chemotherapeutic drugs, docetaxel and etoposide, judging from significantly reduced IC50 value

226 n chemotherapeutics (such as doxorubicin and etoposide), leading to the accumulation of cytotoxic enz

227 e, adding MTAs to radiation, doxorubicin, or etoposide led to more sustained gamma-H2AX levels.

228 ethotrexate (MAP) or MAP plus ifosfamide and etoposide (MAPIE) using concealed permuted blocks with t

229 hoblastic neoplasia (GTN) frequently receive etoposide, methotrexate, and dactinomycin alternating we

230 5 to 1.1) and also for patients treated with etoposide, methotrexate, and dactinomycin followed by cy

231 r high-dose cytarabine plus daunorubicin and etoposide; of these, 18 showed association (P < .05) wit

232 onstrate that DSBs induced in pre-B cells by etoposide or bleomycin inhibit recombination of Igkappa

233 wing treatment with the DNA-damaging agents, etoposide or camptothecin, BRCA1 is required for the act

234 Cellular responses to DNA damage induced by etoposide or doxorubicin include down-regulation of endo

235 preparations of mammalian cells treated with etoposide or electrochemically induced DNA damage condit

236 accumulate in normal human cells exposed to etoposide or infected by an E1B 55-kDa protein-null muta

237 otherapy consisting of a platinum agent plus etoposide or irinotecan.

238 However, DCA, associated with etoposide or irradiation, induced a Bax-dependent apopto

239 n stimulated with apoptotic triggers such as etoposide or vesicular stomatitis virus infection, but d

240 how that DSBs induced by ionizing radiation, etoposide, or bleomycin suppress Rag1 and Rag2 mRNA leve

241 autophagy induced by amino acid starvation, etoposide, or interleukin-3 withdrawal did not affect ce

242 is was induced by exposure to actinomycin D, etoposide, or tunicamycin, with each agent triggering a

243 to two chemotherapeutic drugs, bleomycin and etoposide (P < 0.001).

244 se (GR) received four cycles of platinum and etoposide (PE), for total doses of platinum 420 mg/m(2)

245 patients treated with vincristine sulphate, etoposide phosphate, and carboplatin (VEC).

246 r placebo, combined with up to six cycles of etoposide plus cisplatin or carboplatin every 3 weeks, u

247 approach using high-dose consolidation with etoposide plus cytarabine (EA); three, progression-free

248 motherapy with mitoxantrone, cytarabine, and etoposide preceded, or not, by a course of GO (6 mg/m(2)

249 Infusional etoposide, prednisone, infusional vincristine, infusiona

250 received six cycles of dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, an

251 n, vincristine, and prednisone or rituximab, etoposide, prednisone, vincristine, cyclophosphamide, an

252 ilized by antitopoisomerase II drugs such as etoposide, providing the opportunity for illegitimate en

253 we have found several possible indicators of etoposide resistance operating in MCF7VP cells, includin

254 ulate antiapoptotic factor Bcl-2 and induced etoposide resistance.

255 Carboplatin- and etoposide-resistant MCC cell lines exhibited increased e

256 Our data show etoposide's antibacterial activity is due to DNA gyrase

257 Finally, etoposide's immunomodulatory effects were similar in wil

258 the death response to other stimuli such as etoposide, staurosporine, or UV remained fully intact.

259 hibitor NSC23766 attenuated doxorubicin- and etoposide-stimulated H2AX phosphorylation, induction of

260 d reduce tumor growth and sensitize cells to etoposide, suggesting a clinical application of miRNAs a

261 by R-HDS (cyclophosphamide, cytarabine, and etoposide) supported by autologous stem-cell transplanta

262 Thus, etoposide therapy can selectively ablate effector T cell

263 The addition of etoposide to CHOP resulted in superior PFS in patients <

264 The addition of etoposide to cyclophosphamide, doxorubicin, vincristine,

265 rmal cells, and it acts synergistically with etoposide to kill cancer cells in vitro and slow tumor g

266 o not support the addition of ifosfamide and etoposide to postoperative chemotherapy in patients with

267 Etoposide-treated mice show no or significantly ameliora

268 evated in SI stem/progenitor cells of fasted etoposide-treated mice, which importantly correlated wit

269 iferation and increase in differentiation in etoposide-treated neurospheres.

270 served when p53 was activated in response to etoposide treatment and remained lower than those measur

271 Etoposide treatment combined with FAIM2 inhibition also

272 Etoposide treatment efficacy was proven by ex vivo antic

273 uction of endogenous Ei24 expression through etoposide treatment similarly inhibited nuclear import i

274 ments responded in a heterogeneous manner to etoposide treatment, which could be determined only by t

275 cell survival to preserve SI integrity after etoposide treatment.

276 ous metastasis in the presence or absence of etoposide treatment.

277 reduced number of gammaH2AX foci induced by etoposide treatment.

278 eated DG75 Burkitt lymphoma cells, following etoposide treatment.

279 itizes HTLV-1-infected T-cells to ABT-737 or etoposide treatment.

280 le-stranded break (DSB) sites in response to etoposide treatment.

281 75H-expressing cancer cells to cisplatin and etoposide treatments.

282 Thus, etoposide treats HLH by selectively eliminating patholog

283 t not with anti-EGFR antibody (Cetuximab) or etoposide, triggers a burst in emission of exosome-like

284 etespib synergized with both doxorubicin and etoposide, two topoisomerase II inhibitors commonly used

285 ng vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in standard-risk localized disease (NCT

286 At Indiana University, we recommend etoposide (VP-16), ifosfamide and cisplatin (VIPx4) inst

287 apeutic agents such as doxorubicin (Dox) and etoposide (VP-16).

288 , GSK2830371 enhanced doxorubicin- (Dox) and etoposide- (VP-16) induced cytotoxicity in a subset of N

289 For cisplatin-etoposide vs carboplatin-paclitaxel, there was no signif

290 Cisplatin-etoposide was associated with higher grade 3 to 4 hemato

291 apoptosis induction in neuroblastoma cells, etoposide was ineffective for glioblastoma cell lines.

292 as administered (in patients age > 60 years, etoposide was omitted).

293 RT) with carboplatin-paclitaxel or cisplatin-etoposide were identified using electronic databases (ME

294 hibitors in combination with camptothecin or etoposide were more complicated.

295 Similarly, adding a third drug to etoposide with carboplatin does not seem to substantiall

296 r first-line chemotherapy with cisplatin and etoposide with or without bleomycin.

297 boplatin, cyclophosphamide, vincristine, and etoposide with or without topotecan, vincristine, and do

298 antibacterial QPT-1 and the anticancer drug etoposide with Staphylococcus aureus DNA gyrase, showing

299 pathway and suppressed senescence caused by etoposide without affecting DNA damage response, p53/p21

300 al product precursor of the chemotherapeutic etoposide, yet only part of its biosynthetic pathway is